MedTrace Logo

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

NCT00055653 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2011-03-07

No results posted yet for this study

Summary

RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.

PURPOSE: Phase II trial to study the effectiveness of allogeneic umbilical cord blood transplantation in treating patients who have leukemia, lymphoma, or nonmalignant hematologic disorders.

Conditions

Interventions

BIOLOGICAL

anti-thymocyte globulin

BIOLOGICAL

filgrastim

DRUG

busulfan

DRUG

cyclophosphamide

DRUG

cyclosporine

DRUG

fludarabine phosphate

DRUG

melphalan

DRUG

methylprednisolone

PROCEDURE

umbilical cord blood transplantation

RADIATION

radiation therapy

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Roswell Park Cancer Institute

    lead OTHER

Principal Investigators

  • Philip L. McCarthy, MD · Roswell Park Cancer Institute

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2003-09-30
Completion
2005-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00055653 on ClinicalTrials.gov